Viewing data from:

PROBENECID

ANDA

PROBENECID | A083740 | IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Probenecid (2023)

Total Spending

$6.3M

Total Claims

58,647

Beneficiaries

15,132

Avg Cost/Unit

$1.04

Spending Trend

$5.2M(2019)→$5.7M(2020)→$7.3M(2021)→$6.9M(2022)→$6.3M(2023)

YoY Change:-6.2%

5yr CAGR:+9.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs7 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVPROBENECID USP

DMF 18691971

IPCA LABORATORIES LTDPROBENECID USP

DMF 92371991

COHANCE LIFESCIENCES LTDPROBENECID USP

DMF 360732021

SCL LIFESCIENCES LTDPROBENECID USP

DMF 362342021

GANES CHEMICALS INC PENNSVILLE DIVInactivePROBENECID

DMF 19691972

GANES CHEMICALS INC PENNSVILLE DIVInactivePROBENECID

DMF 27751976

WARD BLENKINSOP AND CO LTDInactivePROBENECID

DMF 32601978

SUNEETA LABORATORIES LTDInactivePROBENECID USPXX

DMF 43221981

SALSBURY CHEMICALS INCInactivePROBENECID USP

DMF 51351983

KAMUD DRUGS PVT LTDInactivePROBENECID USP

DMF 226402009

DK PHARMA CHEM PVT LTDInactivePROBENECID USP

DMF 273662013

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 500MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: May 9, 1984

No patent or exclusivity listings for this strength.